First registration for successful vaccine against dengue fever

First registration for successful vaccine against dengue fever

We are searching data for your request:

Forums and discussions:
Manuals and reference books:
Data from registers:
Wait the end of the search in all databases.
Upon completion, a link will appear to access the found materials.

Dengue fever caused by viruses has developed into one of the most dangerous infectious diseases in the world within a few decades. According to estimates by the World Health Organization (WHO), there are 50 to 100 million dengue infections worldwide each year; around 40 percent of all people now live in risk areas. Mexico has now become the first country to approve a vaccine against the dangerous tropical disease.

Vaccine Tested on More Than 40,000 People Mexico is the first country in the world to have a dengue vaccine approved. As the news agency "dpa" reports, citing the Mexican Ministry of Health, the drug was developed by the French pharmaceutical company Sanofi Pasteur and tested in advance for over two years. Sanofi has therefore carried out a clinical study with over 40,000 people to test that the vaccine should prevent more than 60 percent of all dengue infections and more than 90 percent of severe dengue infections in the future.

Suddenly high fever and severe bone pain. Dengue fever is a viral disease that is transmitted by certain mosquito species of the genus Aedes. However, transmission from person to person is not possible. A distinction is made between the "classic" course and the so-called "hemorrhagic dengue fever". In the first case, a high fever suddenly appears shortly after the infection, and sufferers also suffer from extremely strong muscle, bone and joint pain (“breakbone fever”). Sometimes there is also a blotchy rash, and accompanying general symptoms such as headache, nausea and vomiting, constipation, diarrhea or swelling of the lymph nodes are possible. The symptoms usually subside over the course of a week, and after about two weeks the disease usually heals almost completely.

Hemorrhagic dengue fever is a severe form, which occurs primarily in children and adolescents. Although this begins in a similar way to the classic form, the condition of the person concerned deteriorates massively after a short time. Among other things, bleeding occurs (e.g. in the gastrointestinal area), severe loss of fluid and a weak pulse. If hemorrhagic dengue fever is not treated appropriately, life-threatening shock with circulatory failure (“dengue shock syndrome”) can result from loss of fluid and blood.

32,000 people become infected in Mexico The disease is particularly common in the tropics and subtropics, with Central and South America, Southeast Asia, India, Pakistan and certain areas in Africa and Australia being particularly badly affected. Around 40 percent of the population live in risk areas and the number of new cases worldwide increases every year. In the meantime, the WHO is expecting up to 100 million new infections a year. According to the "dpa", more than 32,000 people were infected in Mexico alone last year. According to this, 3.2 billion pesos (approx. 174 million euros) were spent on treating the patients - around 2.5 percent of the total health budget. (No)

Author and source information

Video: NTG: Press conference of Sanofi Pasteur on dengue vaccine Dengvaxia